Amaris Clinicals (Amaris), the Clinical Research Organization (CRO) division of Caplin Point Laboratories, located at Chennai, has completed a virtual audit from United States Food and Drug Administration (USFDA) with NIL observations.
The company targets approvals on mutual recognition basis from other regulatory bodies, including ones from Latin America, a key geography for Caplin Point.
Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.
